All Serum Institute of India articles
-
NewsBrazil, Malaysia, and Thailand set to start global clinical trial to test promising dengue treatment
Following a licensing agreement signed between the Serum Institute of India (SII) and DNDi, a Phase III clinical trial is expected to begin early next year, with the aim of developing a safe, effective, and globally accessible therapeutic for dengue.
-
News CEPI fast-tracks three Bundibugyo ebolavirus vaccine candidates
The Coalition for Epidemic Preparedness Innovations (CEPI) will urgently accelerate development of three investigational vaccines targeting the Bundibugyo ebolavirus that has caused a rapidly spreading epidemic in the Democratic Republic of the Congo (DRC) and neighbouring Uganda.
-
NewsExperts convened by WHO advise on candidate treatments and vaccines for Ebola disease caused by Bundibugyo virus
In response to the current outbreak of Ebola disease caused by Bundibugyo virus, WHO convened several of its expert and advisory groups to assess potential vaccines and therapeutics for both prevention and treatment of Bundibugyo virus disease (BVD).
-
NewsMalaria vaccine mimics natural immunity with high precision
A detailed analysis reveals one of the reasons why the R21/Matrix-M malaria vaccine works so well: the antibodies generated following vaccination are indistinguishable from those found in people who have been infected by the parasites.
-
NewsWHO prequalifies a second malaria vaccine
WHO has added the R21/Matrix-M malaria vaccine to its list of prequalified vaccines.
-
NewsNew vaccine boosts hopes of eliminating meningitis across Africa
A trial of a new vaccine against meningococcal disease, a cause of meningitis and blood poisoning, has found that it is safe and induces a strong immune response across five strains of meningococcal bacteria: A, C, W, Y and X.